San Diego, United States
PetDx, known as The Liquid Biopsy Company for Pets™, is a promising San Diego-based startup revolutionizing the pet health industry. The company specializes in molecular diagnostics, leveraging the power of genomics to enhance pet care. A standout in their offerings is OncoK9®, a pioneering multi-cancer early detection (MCED) test. This groundbreaking product facilitates the early detection of cancer in dogs through a simple blood draw, employing advanced next-generation sequencing (NGS) technology and proprietary bioinformatic algorithms.
Founded in 2019, PetDx operates within the biotechnology, health care, and life sciences industries. The company is headquartered in the United States and has drawn significant attention from investors. In December of 2021, they secured a $62.00M Series B investment from reputable investors including Torch Capital, Valor Equity Partners, and LabCorp among others. This substantial financial backing highlights investor confidence in their innovative approach to pet health diagnostics.
